DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 74 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Positive impactResults

Glenmark Pharmaceuticals - 10 midcap stocks with over 150% profit growth in Q1FY27

The Economic Times 10 hrs ago·6 Sept 2026, 9:44 am

Glenmark Pharmaceuticals has been identified among a select group of midcap stocks that have delivered over 150% profit growth in the first quarter of fiscal year 2027. This exceptional performance highlights the company's ability to scale its operations and boost earnings significantly in a short period. The stock's inclusion in this list signals strong operational execution and market positioning.

For investors, this development is a key indicator of the company's financial health and its potential to sustain growth. It reflects the broader strength of the midcap sector, where nimble companies are capturing market share. However, investors should monitor whether this growth momentum continues in the upcoming quarters.

Moving forward, the focus should be on Glenmark's ability to maintain this trajectory. Key areas to watch include its product pipeline, export market performance, and any strategic expansions. Consistent delivery on these fronts will be crucial for sustaining investor confidence.

Excerpt from The Economic Times

High year-on-year (YoY) quarterly net profit growth indicates a substantial improvement in a company's profitability compared with the same quarter last year. Based on the latest June 2026 quarter results, data from StockEdge's profitability scan shows that, within the NSE Midcap segment, the top 10 companies reported…

Read the original at The Economic Times

Affected stocks

Bullish1 stock

Glenmark Pharmaceuticals

GLENMARK Bullish

₹2,437.20

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

Concerns Glenmark Pharmaceuticals (GLENMARK).
Category: Results.
AI reads the tone as positive (potentially bullish) for the stock.

Why it matters

A routine update for Glenmark Pharmaceuticals. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at The Economic Times.